B-Y. Ryoo

746 total citations · 1 hit paper
36 papers, 581 citations indexed

About

B-Y. Ryoo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, B-Y. Ryoo has authored 36 papers receiving a total of 581 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 13 papers in Hepatology. Recurrent topics in B-Y. Ryoo's work include Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Gastric Cancer Management and Outcomes (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). B-Y. Ryoo is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Gastric Cancer Management and Outcomes (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). B-Y. Ryoo collaborates with scholars based in South Korea, United States and Germany. B-Y. Ryoo's co-authors include Y-K. Kang, Jia-Lin Lee, M.-H. Ryu, Shuai Yang, H.-M. Chang, Hye Jin Kang, Wonseok Kang, Tae‐Won Kim, Ann‐Lii Cheng and Heon‐Jin Lee and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

B-Y. Ryoo

31 papers receiving 577 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

2022 135 citations Masatoshi Kudo, Philippe Merle et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B-Y. Ryoo South Korea	9	332	313	166	153	115	36	581
M.-H. Ryu South Korea	13	364 1.1×	295 0.9×	196 1.2×	67 0.4×	140 1.2×	27	578
Fabiola Lorena Rojas Llimpe Italy	10	498 1.5×	500 1.6×	217 1.3×	57 0.4×	135 1.2×	32	791
Makio Gamoh Japan	11	248 0.7×	328 1.0×	109 0.7×	45 0.3×	95 0.8×	49	484
Naofumi Eriguchi Japan	16	216 0.7×	324 1.0×	385 2.3×	197 1.3×	48 0.4×	60	716
Shuichi Ishiyama Japan	11	326 1.0×	293 0.9×	295 1.8×	82 0.5×	128 1.1×	33	597
Ioannis T. Konstantinidis United States	15	435 1.3×	579 1.8×	673 4.1×	87 0.6×	39 0.3×	28	915
Laura E. Horvath United States	8	226 0.7×	337 1.1×	96 0.6×	50 0.3×	32 0.3×	15	526
Francesca Erroi Italy	14	189 0.6×	328 1.0×	307 1.8×	27 0.2×	57 0.5×	32	587
Jacqui Oates United Kingdom	10	464 1.4×	773 2.5×	550 3.3×	54 0.4×	100 0.9×	11	1.1k
Jwa Hoon Kim South Korea	11	112 0.3×	182 0.6×	81 0.5×	75 0.5×	32 0.3×	30	348

Countries citing papers authored by B-Y. Ryoo

Since Specialization

Citations

This map shows the geographic impact of B-Y. Ryoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B-Y. Ryoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B-Y. Ryoo more than expected).

Fields of papers citing papers by B-Y. Ryoo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B-Y. Ryoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B-Y. Ryoo. The network helps show where B-Y. Ryoo may publish in the future.

Co-authorship network of co-authors of B-Y. Ryoo

This figure shows the co-authorship network connecting the top 25 collaborators of B-Y. Ryoo. A scholar is included among the top collaborators of B-Y. Ryoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B-Y. Ryoo. B-Y. Ryoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hong, Jung Yong, Maxime Chénard-Poirier, B-Y. Ryoo, et al.. (2025). 9O Phase I/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: Updated safety and pharmacokinetic analysis. ESMO Open. 10. 104165–104165. 1 indexed citations

Saborowski, Anna, Jaewon Hyung, Il Hwan Kim, et al.. (2024). 58P Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials. Annals of Oncology. 35. S235–S235.

Mercadé, T. Macarulla, C. Benedikt Westphalen, Hiroki Imaoka, et al.. (2024). 1519P Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study. Annals of Oncology. 35. S928–S929.

Jiang, Hong, B-Y. Ryoo, Maxime Chénard-Poirier, et al.. (2023). 1046P Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results. Annals of Oncology. 34. S634–S634. 5 indexed citations

Jeong, Hyehyun, Kwang Pyo Kim, Jae Ho Jeong, et al.. (2023). 104P Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA). Annals of Oncology. 34. S221–S221. 1 indexed citations

Kim, Stéfano, et al.. (2023). 989P Disease etiology and efficacy outcomes with atezolizumab plus bevacizumab (atezo-bev) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Multinational retrospective analysis. Annals of Oncology. 34. S609–S610. 1 indexed citations

Ryoo, B-Y., Kwang Pyo Kim, Hong Jae Chon, et al.. (2023). 156P Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial. Annals of Oncology. 34. S1535–S1536. 1 indexed citations

Kudo, Masatoshi, Philippe Merle, Tim Meyer, et al.. (2022). LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Annals of Oncology. 33. S1401–S1401. 135 indexed citations breakdown →

Chan, Stephen L., et al.. (2022). LBA1 A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to immune checkpoint inhibitor-based treatment. Annals of Oncology. 33. S1454–S1454. 3 indexed citations

10.

Kim, Kwang Pyo, et al.. (2022). 55P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC). Annals of Oncology. 33. S565–S565. 9 indexed citations

11.

Cheon, Jaekyung, et al.. (2020). 178P Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis. Annals of Oncology. 31. S1308–S1308. 1 indexed citations

12.

He, Aiwu Ruth, Kazushi Numata, Kyung Ho Lee, et al.. (2020). 986P Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC). Annals of Oncology. 31. S690–S690. 4 indexed citations

13.

Cho, HyungJoon, et al.. (2017). Prognostic implication of inflammation-based prognostic scores in patients with intrahepatic cholangiocarcinoma (iCCA) treated with first-line Gemcitabine plus Cisplatin (GEMCIS). Annals of Oncology. 28. v244–v244. 1 indexed citations

14.

Qin, Shukui, et al.. (2017). Final data from a phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC). Annals of Oncology. 28. v239–v239.

15.

Ryoo, B-Y., et al.. (2017). Outcomes and predictive markers of trastuzumab-containing 1st-line chemotherapy in patients with HER2-positive advanced gastric cancer. Annals of Oncology. 28. x61–x61. 1 indexed citations

16.

Ryu, M.-H., Yubin Kang, Kwang Pyo Kim, et al.. (2016). Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer. Annals of Oncology. 27. vi234–vi234. 14 indexed citations

17.

Kang, Y-K., Changhoon Yoo, B-Y. Ryoo, et al.. (2013). Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. British Journal of Cancer. 109(9). 2309–2315. 49 indexed citations

18.

Yoon, Dok Hyun, M.-H. Ryu, Heon‐Jin Lee, et al.. (2012). Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. British Journal of Cancer. 106(6). 1039–1044. 70 indexed citations

19.

Ryoo, B-Y., et al.. (2006). A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. British Journal of Cancer. 94(7). 959–963. 56 indexed citations

20.

Kang, Yoon‐Koo, et al.. (1999). A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 44(6). 518–521. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact